发明名称 |
Soluble Mediator |
摘要 |
The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject. |
申请公布号 |
US2015259412(A1) |
申请公布日期 |
2015.09.17 |
申请号 |
US201314440703 |
申请日期 |
2013.03.25 |
申请人 |
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH |
发明人 |
Harrison Leonard Charles;Rashidi Maryam;Zhang Yuxia |
分类号 |
C07K16/24;G01N33/50;G01N33/68 |
主分类号 |
C07K16/24 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating or preventing sepsis or multiple sclerosis in a subject, the method comprising administering a therapeutically effective amount of any one or more of:
i) a soluble CD52 glycoprotein, ii) a fusion protein comprising soluble CD52 glycoprotein as a first protein, and a second protein; iii) a polynucleotide encoding the peptide portion of soluble CD52 glycoprotein of part i) or the fusion protein of part ii); iv) a vector comprising the polynucleotide of part iii); v) an isolated cell comprising the polynucleotide of part iii) or the vector of part iv); vi) an isolated CD52hi cell capable of producing soluble CD52 glycoprotein; vii) an isolated cell population comprising a plurality of CD52hi cells capable of producing soluble CD52 glycoprotein; viii) cell culture medium, or a fraction thereof comprising soluble CD52 glycoprotein, isolated from a cell culture comprising the cell of part vi) or the cell population of part vii); ix) an agent capable of increasing the level of expression of soluble CD52 glycoprotein by a cell; and x) a pharmaceutical composition comprising any one or more of i) to ix) and a pharmaceutically acceptable carrier,to the subject. |
地址 |
Melbourne, Victoria AU |